This clinical trial focuses on treating Parkinson’s Disease, a progressive nervous system disorder that affects movement. The study evaluates a treatment called Lecigon, which is an intestinal gel containing three active substances: levodopa, entacapone, and carbidopa. These medications work together to help control the movement symptoms associated with Parkinson’s Disease.
The purpose of this research is to determine if Lecigon therapy is more effective than standard medical treatment in managing certain behavioral and neuropsychiatric symptoms that can occur in Parkinson’s Disease patients. These symptoms include mood changes and behavioral complications that may develop during the course of the disease.
The study treatment involves delivering the medication directly into the intestine as a gel. Patients will receive treatment for up to 12 months, during which time their symptoms and response to the medication will be monitored. The medication is designed to provide more consistent control of Parkinson’s Disease symptoms compared to traditional oral medications.



Germany